{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:16:26Z","timestamp":1788236186322,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Pers. Med.","JPM"],"abstract":"<jats:p>Background\/Objectives: Immunotherapy using immune checkpoint inhibitors has transformed the treatment of multiple solid tumours. However, the clinical response to programmed death receptor (PD-1) and its ligand (PD-L1) inhibitors remains heterogeneous. We have previously shown that host-related factors such as body mass index (BMI) may modulate the efficacy of immunotherapy. The aim of this study was to determine whether body composition, measured with bioelectrical impedance analysis (BIA) before treatment initiation, is a prognostic factor for survival outcomes in patients treated with PD-1\/PD-L1 inhibitors, independently of tumour type and stage. Methods: In this prospective, single-centre observational study, patients with solid tumours underwent baseline body composition assessment using multifrequency bioelectrical impedance analysis (BIA) before initiation of PD-1\/PD-L1 inhibitor therapy. Overall survival (OS), progression-free survival (PFS), and treatment-related adverse events were evaluated using Kaplan\u2013Meier analyses and multivariable Cox regression models adjusted for tumour stage and metastatic status. Results: A total of 80 patients with solid tumours were included in the study. The median age was 67 years, and 48 (60.0%) were male. Higher BMI (\u226525 kg\/m2) and elevated body fat percentage (%BF) were associated with more favourable survival outcomes. After adjustment for tumour stage and metastatic status, BMI \u2265 25 kg\/m2 was associated with a lower risk of death (HR 0.286, 95% CI 0.087\u20130.941; p = 0.039). Similar results were observed for elevated %BF (HR 0.289, 95% CI 0.087\u20130.963; p = 0.036). Neither BMI nor %BF was significantly associated with the occurrence of confirmed immune-related adverse events. Conclusions: Baseline BMI and body fat percentage were associated with survival outcomes in this exploratory cohort of patients receiving PD-1\/PD-L1 inhibitors. These findings should be considered exploratory and hypothesis-generating and require confirmation in larger, tumour-specific prospective studies.<\/jats:p>","DOI":"10.3390\/jpm16090457","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:55:56Z","timestamp":1788155756000},"page":"457","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1\/PD-L1 Inhibitors: A Prospective Exploratory Study"],"prefix":"10.3390","volume":"16","author":[{"given":"\u00c1ngela","family":"Morell","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Universidad San Pablo-CEU, CEU Universities, Urbanizaci\u00f3n Montepr\u00edncipe, Boadilla del Monte, 28668 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Morell","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Universitario de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6633-1485","authenticated-orcid":false,"given":"Ainhoa","family":"Aranguren","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Universitario de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9795-8762","authenticated-orcid":false,"given":"Jacobo","family":"Rogado","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-4046","authenticated-orcid":false,"given":"Miguel","family":"Sampedro","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Mond\u00e9jar","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"Medical Oncology Department, Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"C\u00e1tedra de Medicina Personalizada de Precisi\u00f3n, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-3444","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Colomer","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"Medical Oncology Department, Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"C\u00e1tedra de Medicina Personalizada de Precisi\u00f3n, Universidad Aut\u00f3noma de Madrid, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-2051","authenticated-orcid":false,"given":"M. Paz","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Centro de Metabol\u00f3mica y Bioan\u00e1lisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanizaci\u00f3n Montepr\u00edncipe, Boadilla del Monte, 28668 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3053-7426","authenticated-orcid":false,"given":"Esther","family":"Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Universitario de la Princesa, 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Universitario de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Allen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00262-020-02680-y","article-title":"Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"69","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hahn, A.W., Venkatesh, N., Msaouel, P., and McQuade, J.L. (2023). The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms. Cells, 12.","DOI":"10.3390\/cells12212551"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/mco.2023.2703","article-title":"Prognostic value of obesity in patients with cancer treated with immune checkpoint inhibitors: An updated metaanalysis and systematic review","volume":"20","author":"Guo","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1751548","DOI":"10.1080\/2162402X.2020.1751548","article-title":"Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies","volume":"9","author":"Rogado","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70494","DOI":"10.1002\/mco2.70494","article-title":"Obesity Paradox in Cancer: A Complex Interplay Between Risk and Therapeutic Outcomes","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1055-9965.EPI-16-0439","article-title":"The Obesity Paradox in Cancer-Moving Beyond BMI","volume":"26","author":"Williams","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13679-022-00488-8","article-title":"Criterion-related validity of field-based methods and equations for body composition estimation in adults: A systematic review","volume":"11","author":"Caraballo","year":"2022","journal-title":"Curr. Obes. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Branco, M.G., Mateus, C., Capelas, M.L., Pimenta, N., Santos, T., M\u00e4kitie, A., Ganh\u00e3o-Arranhado, S., Trabulo, C., and Ravasco, P. (2023). Bioelectrical Impedance Analysis (BIA) for the Assessment of Body Composition in Oncology: A Scoping Review. Nutrients, 15.","DOI":"10.3390\/nu15224792"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2023.01.030","article-title":"Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy\u2014A systematic review and meta-analysis","volume":"184","author":"Trinkner","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ajcn\/72.3.694","article-title":"Healthy percentage body fat ranges: An approach for developing guidelines based on body mass index","volume":"72","author":"Gallagher","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_16","first-page":"566","article-title":"Assessment methods in human body composition","volume":"11","author":"Lee","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Naik, A., Monjazeb, A.M., and Decock, J. (2019). The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01940"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","article-title":"Obesity induces PD-1 on macrophages to suppress anti-tumour immunity","volume":"630","author":"Bader","year":"2024","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513948","DOI":"10.1155\/2010\/513948","article-title":"Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review","volume":"2010","author":"Fain","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/er.2010-0030","article-title":"Paracrine and endocrine effects of adipose tissue on cancer development and progression","volume":"32","author":"Park","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"150437","DOI":"10.1016\/j.bbrc.2024.150437","article-title":"Mechanisms by which obesity regulates inflammation and anti-tumor immunity in cancer","volume":"733","author":"Miracle","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Buonaiuto, R., Napolitano, F., Parola, S., De Placido, P., Forestieri, V., Pecoraro, G., Servetto, A., Formisano, L., Formisano, P., and Giuliano, M. (2022). Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer. Biomolecules, 12.","DOI":"10.3390\/biom12101394"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.4049\/jimmunol.2001152","article-title":"Leptin Augments Antitumor Immunity in Obesity by Repolarizing Tumor-Associated Macrophages","volume":"207","author":"Dudzinski","year":"2021","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Achamrah, N., Colange, G., Delay, J., Rimbert, A., Folope, V., Petit, A., Grigioni, S., D\u00e9chelotte, P., and Co\u00ebffier, M. (2018). Comparison of body composition assessment by DXA and BIA according to the body mass index: A retrospective study on 3655 measures. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200465"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: A retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: A systematic review and meta-analysis","volume":"70","author":"Samson","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","article-title":"Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhang, D., Shah, N.J., Cook, M., Blackburn, M., Serzan, M.T., Advani, S., Potosky, A.L., Atkins, M.B., and Braithwaite, D. (2021). Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers, 13.","DOI":"10.3390\/cancers13236109"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Spagnolo, C.C., Ruggeri, R.M., Alibrandi, A., Lagan\u00e0, M., Speranza, D., Cannav\u00f2, S., Berretta, M., and Santarpia, M. (2025). Immune checkpoint inhibitor-induced toxicity: A real-world analysis of the role of BMI. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1659977"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s12094-022-02887-8","article-title":"Excess weight and anti-PD-1 immune checkpoint inhibitor\u2019s outcomes in non-small cell lung cancer","volume":"24","author":"Rogado","year":"2022","journal-title":"Clin. Transl. Oncol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/9\/457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:38:24Z","timestamp":1788233904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/9\/457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jpm16090457"],"URL":"https:\/\/doi.org\/10.3390\/jpm16090457","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}